Scarica l'app Stockscreener
89.53
0.61%
0.54
Pre-mercato:
89.90
0.37
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$88.99
Aprire:
$88.99
Volume 24 ore:
2.70M
Relative Volume:
0.79
Capitalizzazione di mercato:
$35.11B
Reddito:
$4.15B
Utile/perdita netta:
$535.20M
Rapporto P/E:
66.81
EPS:
1.34
Flusso di cassa netto:
$575.20M
1 W Prestazione:
+6.55%
1M Prestazione:
+3.71%
6M Prestazione:
+1.34%
1 anno Prestazione:
+39.89%
Intervallo 1D:
$88.63
$89.76
Intervallo di 1 settimana:
$84.25
$89.76
Portata 52W:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
89.53 | 34.89B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Earnings To Watch: DexCom (DXCM) Reports Q2 Results Tomorrow - Yahoo Finance
Dexcom launches AI-powered meal logging for CGM users - MassDevice
Dexcom Rolls Out AI-Powered Meal Logging for Stelo CGM - Medical Product Outsourcing
Dexcom's AI-Powered Smart Food Logging: A Game-Changer in Glucose Management and Metabolic Health Tech - AInvest
Dexcom adds AI-powered food logging to Stelo glucose monitor By Investing.com - Investing.com India
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio | DXCM Stock News - GuruFocus
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio - DexCom Investor Relations
Building a $33B Digital Health Juggernaut | Dexcom Chairman & CEO Kevin Sayer - iHeart
What is the risk reward ratio of investing in DexCom Inc. stockFree Market Volatility Navigation Tips - jammulinksnews.com
What catalysts could drive DexCom Inc. stock higher in 2025Achieve rapid financial growth with expert help - jammulinksnews.com
How Dexcom leverages AI to tackle diabetes - Constellation Research
Why DexCom Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - metal.it
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? - MSN
Mizuho Lifts PT on DexCom (DXCM) to $100 From $95, Keeps an Outperform Rating - MSN
What drives DexCom Inc. stock pricePhenomenal wealth increase - PrintWeekIndia
Will DexCom Inc. stock split in the near futureFree Market Volatility Navigation Tips - jammulinksnews.com
Is DexCom, Inc.'s (NASDAQ:DXCM) ROE Of 24% Impressive? - Yahoo Finance
DexCom Takes A Hit As Growth Meets New Headwinds - Finimize
Is DexCom Inc. a good long term investmentFree Investment Case Studies - jammulinksnews.com
What analysts say about DexCom Inc. stockHigh-octane investment gains - jammulinksnews.com
DexCom Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease - simplywall.st
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jul 15 '25 |
Sale |
85.17 |
2,750 |
234,217 |
53,871 |
| Brown Michael Jon | EVP, Chief Legal Officer |
Jul 15 '25 |
Sale |
86.03 |
500 |
43,015 |
94,602 |
0.17%
1.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):